STAT

Opinion: It isn’t crazy to conduct an Ebola clinical trial in a war zone — it’s necessary

The only way to evaluate possible treatments for #Ebola is to test them in a clinical trial, even though the current outbreak is spreading in what's akin to a war…
Health workers move a patient to a hospital in Butembo, Democratic Republic of the Congo, after he was cleared of having Ebola.

The term “randomized controlled trial” conjures up images of sterile, high-tech labs with closely monitored patients hooked up to numerous machines. That’s a far cry from the reality of a brave and groundbreaking trial that began last week in the Democratic Republic of the Congo to investigate lifesaving treatments for Ebola.

The DRC is in the midst of one of the worst Ebola outbreaks it has faced. With at least 260 people killed so far, it is

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks